Evidence map›Paper›PMID 29124649›Full record

ArticleJournal of neuro-oncology2018

Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery.

Mudit Chowdhary, Derick Okwan-Duodu, Jeffrey M Switchenko, Robert H Press, Jaymin Jhaveri, Zachary S Buchwald, Jim Zhong, Bhavana V Chapman, Ranjit S Bindra, Joseph N Contessa and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
  4. Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Mudit ChowdharyDepartment of Radiation Oncology, Rush University Medical Center, 500 South Paulina, Chicago, IL, 60612, USA. mchowdharymd@gmail.com.ORCID http://orcid.org/0000-0001-8546-6077
Derick Okwan-DuoduDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Jeffrey M SwitchenkoBiostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Robert H PressDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Jaymin JhaveriDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Zachary S BuchwaldDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Jim ZhongDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Bhavana V ChapmanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ranjit S BindraDepartment of Therapeutic Radiology and Smilow Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Joseph N ContessaDepartment of Therapeutic Radiology and Smilow Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Henry S ParkDepartment of Therapeutic Radiology and Smilow Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
James B YuDepartment of Therapeutic Radiology and Smilow Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Roy H DeckerDepartment of Therapeutic Radiology and Smilow Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Jeffrey J OlsonDepartment of Neurosurgery and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Nelson M OyesikuDepartment of Neurosurgery and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Ross A AbramsDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Hui-Kuo G ShuDepartment of Radiation Oncology, Rush University Medical Center, 500 South Paulina, Chicago, IL, 60612, USA.
Walter J CurranDepartment of Radiation Oncology, Rush University Medical Center, 500 South Paulina, Chicago, IL, 60612, USA.
Ian R CrockerDepartment of Radiation Oncology, Rush University Medical Center, 500 South Paulina, Chicago, IL, 60612, USA.
Kirtesh R PatelDepartment of Therapeutic Radiology and Smilow Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA. kirtesh@gmail.com.
Emory University · USSmilow Cancer Hospital · USRush University Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

Preclinical evidence suggests angiotensin blockade therapy (ABT) decreases late radiation toxicities. This study aims to investigate the association between ABT and symptomatic radiation necrosis (SRN) following stereotactic radiosurgery (SRS). Resected brain metastases (rBM) and arteriovenous malformation (AVM) patients treated with SRS from 2002 to 2015 were identified. Patients in the ABT cohort were on therapy during SRS and at 1-month follow up. Kaplan Meier method and cumulative incidence model were used to analyze overall survival (OS) and intracranial outcomes. 228 consecutive patients were treated with SRS: 111 with rBM and 117 with AVM. Overall, 51 (22.4%) patients were in the ABT group: 32 (28.8%) in the rBM and 19 (16.2%) in AVM cohorts. Baseline characteristics were similar, except for higher Graded Prognostic Analysis (3-4) in the rBM (ABT: 25.0% vs. non-ABT: 49.0%, p = 0.033) and median age in the AVM (ABT: 51.4 vs. non-ABT: 35.4, p < 0.001) cohorts. In both populations, OS and intracranial efficacy (rBM-local control; AVM-obliteration rates) were statistically similar between the cohorts. ABT was associated with lower 1-year SRN rates in both populations: rBM, 3.1 versus 25.3% (p = 0.003); AVM, 6.7 vs. 14.6% (p = 0.063). On multivariate analysis, ABT was a significant predictive factor for rBM (HR: 0.17; 95% CI 0.03-0.88, p = 0.035), but did not reach statistical significance for AVM (HR: 0.36; 95% CI 0.09-1.52, p = 0.165). ABT use appears to be associated with a reduced risk of SRN following SRS, without detriment to OS or intracranial efficacy. A prospective trial to validate these findings is warranted.

Indexed as

AdultAgedAngiotensin Receptor AntagonistsBrain NeoplasmsCohort StudiesFemaleHumansIntracranial Arteriovenous MalformationsKaplan-Meier EstimateMaleMiddle AgedNecrosisRadiation InjuriesRadiosurgeryTreatment OutcomeAngiotensin Receptor AntagonistsAngiotensin converting enzyme inhibitorAngiotensin receptor blockerArteriovenous malformationBrain metastasesRadiation necrosis

Identifiers

PMID29124649
PMCPMC5784434
OpenAlexW2767754672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.